MedTrace Logo

Autologous Bone Marrow Aspirate Concentrate in Patients Undergoing Meniscectomy

NCT02582489 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-04-14

No results posted yet for this study

Summary

The proposed research study aims to evaluate the effects of autologous bone marrow aspirate concentrate (BMAC) on the development and progression of osteoarthritis (OA) in patients undergoing meniscectomy. This prospective, randomized, double-blind clinical trial will compare patient-reported outcomes, specifically IKDC scores between patients who receive BMAC post-meniscectomy and those who receive a saline control injection. The study will also compare physical examination, MRI, radiographs, and synovial fluid analysis. Our hypothesis is that those who receive the autologous BMAC injection after the procedure will have better outcomes than those who do not.

Conditions

  • Osteoarthritis Post-meniscectomy

Interventions

BIOLOGICAL

Bone Marrow Aspirate Concentrate

Subjects undergoing autologous bone marrow aspirate concentrate will receive an intra-articular injection into the affected knee.

PROCEDURE

Standard Meniscectomy

All subjects will undergo either a partial or complete meniscectomy to treat the torn meniscus.

Sponsors & Collaborators

  • Rush University Medical Center

    lead OTHER

Principal Investigators

  • Brian J Cole, MD, MBA · Midwest Orthopaedics at Rush

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-22
Primary Completion
2026-11-30
Completion
2026-12-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02582489 on ClinicalTrials.gov